reglab/statecodes huggingface dataset:
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-037 - Regulated steroids

Current through Register Vol. 24-14, July 15, 2024
The following drugs are classified as steroids for the
						purposes of
						RCW 69.41.310.
						The drugs designated shall include the following and any synthetic derivatives
						or any isomer, ester, salt, or derivative of the following that act in the same
						manner on the human body:
(1)
					 Anabolicum;
(2) Anadrol;
(3) Anatrofin;
(4) Anavar;
(5) Androxon;
(6) Andriol;
(7) Android;
(8) Bolandiol;
(9) Bolasterone;
(10) Boldenone;
(11) Boldenone undecylenate;
(12) Bolenol;
(13) Bolfortan;
(14) Bolmantalate;
(15) Cheque;
(16) Chlorotestosterone;
(17) Clostebol;
(18) Deca Durabolin;
(19)
					 Dehydrochlormethyl-testosterone;
(20) Delatestyl;
(21) Dianabol; and
(22) Dihydrolone.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-038 - Availability and identity of amygdalin

Current through Register Vol. 24-14, July 15, 2024
(1) Amygdalin (laetrile) may be manufactured
					 and distributed through intrastate commerce in Washington in accordance with
					 all applicable state laws and regulations.
(2) Amygdalin (laetrile) imported into the
					 state of Washington shall be imported in conformity with federal regulations or
					 court decisions.
(3) Under the
					 direction of the commission batches of amygdalin (laetrile) must be made with
					 the costs for required testing, including purity and potency, to be borne by
					 the manufacturer and wholesale distributor. The manufacturer and wholesale
					 distributor is responsible for the quality of the drug product, in accordance
					 with
					 RCW
					 18.64.270.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-043 - Designation of nonnarcotic stimulant drugs for the purposes of RCW 69.50.402 (1)(c)

Current through Register Vol. 24-14, July 15, 2024
The commission hereby designates, the following Schedule
						II controlled substances as nonnarcotic stimulants for purposes of
						RCW
						69.50.402(1)(c):
(1) Amphetamine sulfate in any of its generic
					 forms.
(2) Dextroamphetamine
					 sulfate in any of its generic forms and under the following brand names:
(a) Dexedrine (SKF);
(b) Dexedrine spansules (SKF).
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-045 - Prescribing, dispensing, or administering of Schedule II nonnarcotic stimulants

Current through Register Vol. 24-14, July 15, 2024
The Schedule II stimulants listed in WAC 246-945-043 may
						be prescribed, dispensed, or administered to patients for the following disease
						states or conditions:
(1) Disease
					 states or conditions listed in
					 RCW
					 69.50.402(1)(c)(ii);
					 and
(2) Moderate to severe binge
					 eating disorder in adults.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-047 - Sodium pentobarbital registration disciplinary action

Current through Register Vol. 24-14, July 15, 2024
In addition to any criminal or civil liabilities that may
						occur, the commission may deny, suspend, or revoke registration upon
						determination that:
(1) The
					 registration was procured through fraud or misrepresentation;
(2) The registrant or any agent or employee
					 of the registrant has violated any of the federal or state laws related to
					 drugs, or has violated any of the rules or regulations of the
					 commission.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-050 - Commission authority to control

Current through Register Vol. 24-14, July 15, 2024
Pursuant to the authority granted to the commission in
						RCW
						69.50.201, the commission has considered the
						following factors with regards to each of the substances listed in this chapter
						and in chapter 69.50 RCW:
(1) The
					 actual or relative potential for abuse;
(2) The scientific evidence of its
					 pharmacological effect, if known;
(3) The state of current scientific knowledge
					 regarding the substance;
(4) The
					 history and current pattern of abuse;
(5) The scope, duration, and significance of
					 abuse;
(6) The risk to the public
					 health;
(7) The potential of the
					 substance to produce psychic or psychological dependence liability;
					 and
(8) Whether the substance is an
					 immediate precursor of a substance already controlled under the Uniform
					 Controlled Substances Act (chapter 69.50 RCW).
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-051 - Schedule I

Current through Register Vol. 24-14, July 15, 2024
The commission finds that the following substances have
						high potential for abuse and have no accepted medical use in treatment in the
						United States or that they lack accepted safety for use in treatment under
						medical supervision. In addition to the substances scheduled in
						RCW
						69.50.204 the commission places each of the
						following controlled substances by whatever official name, common or usual
						name, chemical name, or brand name in Schedule I.
(1) Opiates. Unless specifically exempted or
					 unless listed in another schedule, any of the following opiates, including
					 their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers,
					 whenever the existence of these isomers, esters, ethers, and salts is possible
					 within the specific chemical designation:
(a)
					 (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); some other names: Acetyl
					 fentanyl;
(b)
					 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide, its isomers,
					 esters, ethers, salts, and salts of isomers, esters, and ethers; some other
					 names: U-47700;
(c)
					 3,4-dichloro-N-[(1-dimethylamino) cyclohexyl-methyl]benzamide; some other
					 names: AH-7921;
(d)
					 Dextrorphan;
(e)
					 N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide, its isomers, esters, ethers,
					 salts, and salts of isomers, esters, and ethers; some other names: Acryl
					 fentanyl and acry-loylfentanyl;
(f)
					 N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, its isomers, esters, ethers,
					 salts, and salts of isomers, esters, and ethers; some other names: Butyryl
					 fentanyl;
(g)
					 N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-car-boxamide, its isomers,
					 esters, ethers, salts, and salts of iso-mers, esters, and ethers; some other
					 names: Furanyl fentanyl;
(h)
					 N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl) isobutyramide, its isomers,
					 esters, ethers, salts, and salts of isomers, esters, and ethers; some other
					 names: 4-fluoroisobu-tyryl fentanyl and para-fluoroisobutyryl
					 fentanyl;
(i)
					 N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide,
					 its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;
					 some other names: Beta-hydroxythiofentanyl; and
(j) Propheptazine.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-052 - Schedule II

Current through Register Vol. 24-14, July 15, 2024
The commission finds that the following substances have a
						high potential for abuse and have currently accepted medical use in treatment
						in the United States, or currently accepted medical use with severe
						restrictions and that the abuse of the following substances may lead to severe
						psychic or psychological dependence. In addition to the substances listed in
						RCW
						69.50.206, the commission places each of the
						following drugs and other substances by whatever official name, common or usual
						name, chemical name, or brand name in Schedule II.
(1) Coca leaves and any salt, compound,
					 derivative, or preparation of coca leaves (including cocaine and ecgonine and
					 their salts, isomers, derivatives and salts of isomers and derivatives), and
					 any salt, compound, derivative, or preparation thereof which is chemically
					 equivalent or identical with any of these substances, but not including:
(a) Decocainized coca leaves or extractions
					 which do not contain cocaine or ecgonine; or
(b)
					 [123I]ioflupane.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-053 - Schedule II immediate precursors

Current through Register Vol. 24-14, July 15, 2024
The commission finds and designates the following
						substances as being the principal compound used or produced primarily for use
						and which are an immediate chemical intermediary used or likely to be used, in
						the manufacture of a Schedule II controlled substance, the control of which is
						necessary to prevent, curtail or limit manufacture.
(1) Unless specifically exempted or listed in
					 another schedule, any material, compound, mixture or preparation which contains
					 any quantity of the following substances or their salts or isomers having
					 potential for abuse associated with the preparation of controlled substances
					 shall be a Schedule II controlled substance.
(a) Anthranilic acid;
(b) Ephedrine;
(c) Hydriodic acid;
(d) Methylamine;
(e) Phenylacetic acid;
(f) Pseudoephedrine;
(g) Methephedrine;
(h) Lead acetate; and
(i) Methyl formamide.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-055 - Schedule IV

Current through Register Vol. 24-14, July 15, 2024
The commission finds that the following substances have a
						low potential for abuse relative to substances in Schedule III under
						RCW
						69.50.208 and WAC 246-945-054, and have
						currently accepted medical use in treatment in the United States and that the
						abuse of the substances may lead to limited physical dependence or
						psychological dependence relative to the substances in Schedule III. In
						addition to substances listed in
						RCW
						69.50.210, the commission places each of the
						following drugs and substances by whatever official name, common or usual name,
						chemical name, or brand name in Schedule IV.
(1) Narcotic drugs. Unless specifically
					 exempted or unless listed in another schedule, any material, compound, mixture,
					 or preparation containing any of the following narcotic drugs, or their salts
					 calculated as the free anhydrous base or alkaloid, in limited quantities as set
					 in this subsection: 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexa-nol,
					 its salts, optical and geometric isomers, and salts of these isomers (including
					 tramadol).
(2) Depressants. Unless
					 specifically exempted or unless listed in another schedule, any material,
					 compound, mixture, or preparation which contains any quantity of the following
					 substances, including its salts, isomers, and salts of isomers whenever the
					 existence of such salts, isomers, and salts of isomers is possible within the
					 specific chemical designation:
(a)
					 Alfaxalone;
(b)
					 Fospropofol;
(c)
					 Suvorexant.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-056 - Schedule V

Current through Register Vol. 24-14, July 15, 2024
The commission finds that the following substances have
						low potential for abuse relative to substances in Schedule IV under
						RCW
						69.50.210 and WAC 246-945-055 and have
						currently accepted medical use in treatment in the United States and that the
						substances have limited physical dependence or psychological dependence
						liability relative to the substance in Schedule IV. In addition to the
						substances listed in
						RCW
						69.50.212, the commission places each of the
						following drugs and substances by whatever official name, common or usual name,
						chemical name, or brand name in Schedule V.
Depressants. Unless specifically exempted or excluded or
						unless listed in another schedule, any material, compound, mixture, or
						preparation which contains any quantity of the following substances having a
						depressant effect on the central nervous system, including its salts:
(1) Brivaracetam
					 ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] bu-tanamide); also referred to as
					 BRV; UCB-34714; Briviact;
(2)
					 Ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carba-mic acid ethyl
					 ester].
Reviser's note:
The brackets and enclosed
						  material in the text of the above section occurred in the copy filed by the
						  agency.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-060 - Other controlled substance registrants-Requirements

Current through Register Vol. 24-14, July 15, 2024
(1) All persons and firms, except persons
					 exempt from registration, must register with the commission in order to legally
					 possess or use controlled substances.
(2) Persons or firms which are not classified
					 as pharmacies, wholesalers, manufacturers, or researchers will be classified as
					 other controlled substance registrants. Examples of persons or firms in this
					 classification include analytical laboratories, dog handlers/trainers who use
					 dogs for drug detection purposes, school laboratories and other agencies which
					 have a legitimate need to use precursor chemicals as defined in WAC
					 246-945-053.
(3) The applicant for
					 a controlled substance registration must complete and return an application
					 form supplied by the commission. A list of the controlled substances to be
					 used, the purpose for such use, and the names of the persons authorized to
					 access the controlled substances must be listed on the application or on an
					 addendum.
(4) All controlled
					 substances must be stored in a substantially constructed locked cabinet. The
					 registrant shall maintain records in sufficient detail in order to account for
					 the receipt, use, and disposition of all controlled substances. The registrant
					 shall inventory all controlled substances in the possession of the registrant
					 every two years on the anniversary of the issuances of the registration and
					 shall maintain the inventory list for two years. The registrant shall return
					 unwanted, outdated, or unusable controlled substances to the source from which
					 it was obtained or surrendered to the DEA.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-063 - Precursor definitions

Current through Register Vol. 24-14, July 15, 2024
The definitions in this section apply to WAC 246-945-065
						through 246-945-088.
(1) "Restricted product" means any
					 nonprescription product containing any detectable quantity of ephedrine,
					 pseudoephedrine, and phenylpropanolamine or their salts or isomers, or salts of
					 isomers.
(2) "Retailer" means a
					 pharmacy licensed by, or shopkeeper or itinerant vendor registered with, the
					 department of health under chapter 18.64 RCW that sells, dispenses, or
					 otherwise provides restricted products to purchasers.
(3) "Sale" means the transfer, selling, or
					 otherwise furnishing of any restricted product to any person.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-065 - Precursor substance control

Current through Register Vol. 24-14, July 15, 2024
(1)
					 For the purpose of this chapter, in addition to the substances in
					 RCW
					 69.43.010, a precursor substance is any of
					 the following substances or their salts or isomers:
(a) Gamma-butyrolactone (GBL); and
(b) Hydriodic acid.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-070 - Reports of precursor receipt

Current through Register Vol. 24-14, July 15, 2024
(1)
					 Any manufacturer, wholesaler, retailer, or any other person who receives from
					 any source outside the state of Washington any precursor substance listed in
					 WAC 246-945-065 or
					 RCW
					 69.43.010 shall submit a report of such
					 transaction within fourteen days of the receipt of that substance.
(2) The report shall contain the following
					 information:
(a) Name of substance;
(b) Quantity received;
(c) Date received;
(d) Name and address of firm or person
					 receiving substance; and
(e) Name
					 and address of the source selling, transferring, or furnishing the
					 substance.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-072 - Precursor substance monthly reporting

Current through Register Vol. 24-14, July 15, 2024
(1) A permit holder who regularly transfers
					 the same precursor substance to the same recipient may apply to the commission
					 for authorization to submit the report of said transactions on a monthly basis.
					 Requests for monthly reporting authorization must be received at the commission
					 office at least thirty days prior to the commission meeting at which the
					 request will be considered. The commission will review each request to
					 determine if the requirements of RCW 69.43.-010(4), are met and will notify the
					 permit holder of its decision and the reporting format that will be
					 authorized.
(2) A permit holder may
					 also petition the commission to accept the monthly report on a
					 computer-generated basis. The report may be furnished in hard copy, on
					 commission-approved data storage methods or by computer interface with a
					 commission-operated computer. The permit holder is responsible for the accuracy
					 of the report and the prompt correction of any data entry or transmission
					 errors.
(3) The authorization to
					 use monthly reports or computer-generated monthly reports may be rescinded at
					 the commission's discretion and with thirty days' notice.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-075 - Suspicious transactions and reporting requirements

Current through Register Vol. 24-14, July 15, 2024
(1) A manufacturer, wholesaler or distributor
					 who sells, transfers, or furnishes a regulated product to any licensee shall
					 report any suspicious transaction in writing to the commission.
(2) For the purpose of this rule, a regulated
					 product is defined as a product specified in
					 RCW
					 69.43.010(1) or WAC
					 246-945-065.
(3) For the purposes
					 of this rule, a "suspicious transaction" is defined as any sale or transfer
					 that meets any of the following criteria:
(a)
					 Any sale or transfer that would lead a reasonable person to believe that the
					 substance is likely to be used for the purpose of unlawfully manufacturing a
					 controlled substance under chapter 69.50 RCW, based on such factors as:
(i) The amount of the substance involved;
(ii) The method of payment;
(iii) The method of delivery; or
(iv) Any past dealings with any
					 participant in the transaction.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-077 - Precursor substance requirements for the sale of a restricted product

Current through Register Vol. 24-14, July 15, 2024
Unless exempted in
						RCW
						69.43.110, a retailer must:
(1) Verify the purchaser's identity by means
					 of acceptable identification as defined in this chapter;
(2) Ensure that the purchaser is at least
					 eighteen years of age; and
(3)
					 Record all of the information required in WAC 246-945-078 in the record of
					 transaction before completing the sale.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-078 - Record of sales-Electronic methamphetamine precursor tracking

Current through Register Vol. 24-14, July 15, 2024
(1) Unless granted
					 an exemption under
					 RCW
					 69.43.110 upon the sale or attempted sale of
					 a restricted product, each retailer shall enter and electronically transmit the
					 following information to the methamphetamine precursor tracking system prior to
					 completion of the transaction:
(a) Sale
					 transaction information including:
(i) Date
					 and time of the intended purchase;
(ii) Product description;
(iii) Quantity of product to be sold
					 including:
(A) Total grams of restricted
					 product per box;
(B) Number of
					 boxes per transaction.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-080 - Acceptable forms of identification

Current through Register Vol. 24-14, July 15, 2024
Acceptable forms of identification are defined as current
						foreign, federal, state, or tribal government-issued identification which
						include the person's photograph, name, date of birth, signature, and physical
						description. Acceptable forms of identification include, but are not limited
						to:
(1) A valid driver's license or
					 instruction permit issued by any U.S. state or foreign government. If the
					 purchaser's driver's license has expired, he or she must also show a valid
					 temporary driver's license with the expired card.
(2) A United States Armed Forces
					 identification card issued to active duty, reserve, and retired personnel and
					 the personnel's dependents.
(3) A
					 merchant marine identification card issued by the United States Coast
					 Guard.
(4) An identification card
					 issued by any foreign, federal, or state government.
(5) An official U.S. passport or an unexpired
					 foreign passport that contains a temporary I-551 stamp.
(6) An enrollment card issued by the
					 governing authority of a federally recognized Indian tribe located in
					 Washington state, if the enrollment card incorporates security features
					 comparable to those implemented by the department of licensing for Washington
					 state drivers' licenses.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-085 - Maintenance of and access to retail sales records of restricted products

Current through Register Vol. 24-14, July 15, 2024
(1) The retail
					 sales records required under WAC 246-945-078 are confidential and accessible by
					 the commission and law enforcement agencies. Law enforcement may access the
					 retail sales records for criminal investigations when, at a minimum, there is
					 an articulated individualized suspicion of criminal activity.
(2) Each law enforcement agency's
					 administrator, chief, sheriff, or other chief executive officer shall ensure:
(a) Only authorized employees have access to
					 the databases;
(b) Each employee
					 use his or her unique password or access code to access the
					 databases;
(c) Each employee
					 adheres to all state and federal laws regarding confidentiality; and
(d) As employees change, new passwords or
					 access codes are assigned to new employees and passwords of ex-employees or
					 transferred employees are removed.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-087 - Exemptions from electronic reporting

Current through Register Vol. 24-14, July 15, 2024
(1) Pharmacies are exempt from entering
					 purchase information into the methamphetamine precursor tracking system when
					 the sale of products containing ephed-rine, pseudoephedrine, or
					 phenylpropanolamine or their salts or isomers, or salts of isomers is sold
					 pursuant to a prescription written by an authorized practitioner.
(2) A retailer must demonstrate "good cause"
					 to qualify for an exemption from electronic reporting requirements. "Good
					 cause" includes, but is not limited to, situations where the installation of
					 the necessary equipment to access the methamphetamine precursor tracking system
					 is unavailable or cost prohibitive to the retailer.
(a) A retailer must submit a written request
					 on a form provided by the commission, which shall include the following
					 information:
(i) The reason for the
					 exemption; and
(ii) The anticipated
					 duration needed for the exemption.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-088 - Denial of a sale-Override

Current through Register Vol. 24-14, July 15, 2024
(1) The
					 retailer must deny the sale of restricted product to purchasers who are not
					 able to produce acceptable identification or if the sale would violate
					 RCW
					 69.43.110 or federal law.
(2) In the event that the retailer perceives
					 that refusal of the purchase may place them in imminent physical harm, the
					 retailer may use the database safety override function to proceed with the
					 sale, provided that when the threat is no longer perceived, the retailer must
					 immediately contact local law enforcement to report the incident.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart D - Home Dialysis › Section 246-945-090 - Home dialysis program-Legend drugs

Current through Register Vol. 24-14, July 15, 2024
Pursuant to
						RCW
						18.64.257 and
						69.41.032,
						a medicare-approved dialysis center or facility operating a medicare-approved
						home dialysis program may sell, deliver, possess or dispense directly to its
						home dialysis patients in cases or full shelf package lots, if prescribed by a
						physician, the following legend drugs:
(1) Sterile heparin, 1000 u/mL, in
					 vials;
(2) Sterile potassium
					 chloride, 2 mEq/mL, for injection;
(3) Commercially available dialysate;
					 and
(4) Sterile sodium chloride,
					 0.9%, for injection in containers of not less than 150 mL.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart D - Home Dialysis › Section 246-945-091 - Home dialysis program-Pharmacist consultant

Current through Register Vol. 24-14, July 15, 2024
Home dialysis programs involved in the distribution of
						legend drugs as permitted by
						RCW
						18.64.257 and
						69.41.032,
						shall have an agreement with a pharmacist which provides for consultation as
						necessary. This shall include advice on the drug distribution process to home
						dialysis patients and on the location used for storage and distribution of the
						authorized drugs, which shall be reasonably separated from other activities and
						shall be secure.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart D - Home Dialysis › Section 246-945-092 - Home dialysis program-Records

Current through Register Vol. 24-14, July 15, 2024
(1) A record of shipment shall be attached to
					 the prescriber's order and shall include:
(a)
					 The name of the patient;
(b)
					 Strengths and quantities of drugs;
(c) The manufacturers' names;
(d) Date of shipment;
(e) Names of persons who selected, assembled
					 and packaged for shipment; and
(f)
					 The name of the pharmacist or designated individual responsible for the
					 distribution.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart D - Home Dialysis › Section 246-945-093 - Home dialysis program-Quality assurance

Current through Register Vol. 24-14, July 15, 2024
Home dialysis programs involved in the distribution of
						legend drugs as permitted by
						RCW
						18.64.257 and
						69.41.032,
						shall develop a quality assurance program for drug distribution and shall
						maintain records of drug distribution errors and other problems, including loss
						due to damage or theft.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart E - Compounding › Section 246-945-100 - Compounding minimum standards

Current through Register Vol. 24-14, July 15, 2024
(1) All licensees
					 of the commission must comply, at a minimum, with the following chapters of the
					 United States Pharmacopeia (USP) when engaged in compounding nonsterile and
					 sterile products for patient administration or distribution to a licensed
					 practitioner for patient use or administration:
(a) USP General Chapter <795>
					 Pharmaceutical Compounding - Non-sterile Preparations, official as of November
					 1, 2023;
(b) USP General Chapter
					 <797> Pharmaceutical Compounding - Sterile Preparations, official as of
					 November 1, 2023;
(c) USP General
					 Chapter <800> Hazardous Drugs - Handling in Healthcare Settings;
					 and
(d) USP General Chapter
					 <825> Radiopharmaceuticals - Preparation, Compounding, Dispensing, and
					 Repackaging.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 2 - GENERAL LICENSING › Section 246-945-145 - License required

Current through Register Vol. 24-14, July 15, 2024
An individual providing pharmacy services to individuals
					 located in Washington is required to be credentialed by the commission, unless
					 the individual is providing pharmacy services within the scope of their
					 employment, or affiliation, with a Washington licensed nonresident pharmacy or
					 the law otherwise permits the practice.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 2 - GENERAL LICENSING › Section 246-945-150 - Applicable forms

Current through Register Vol. 24-14, July 15, 2024
All applications for initial licensure and renewals must be
					 submitted on forms provided by the commission as well as any other required
					 documentation.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 2 - GENERAL LICENSING › Subpart A - Pharmacy Interns and Pharmacist › Section 246-945-155 - Pharmacy interns-Registration requirements

Current through Register Vol. 24-14, July 15, 2024
(1) Unless otherwise stated, each individual
					 shall register with the commission, as a pharmacy intern before beginning
					 pharmacy practice experiences in Washington state. The commission shall grant a
					 registration to practice pharmacy as a pharmacy intern to an individual who is:
(a) Currently enrolled in a professional
					 degree program of a commission accredited school or college of pharmacy and
					 making satisfactory progress towards meeting the requirements for licensure as
					 a pharmacist;
(b) A graduate of a
					 commission accredited school or college of pharmacy;
(c) A graduate of a school or college of
					 pharmacy located outside the United States who has established educational
					 equivalency by obtaining certification by FPGEC;
(d) Required by the commission to be an
					 intern because the commission has determined the individual needs to complete
					 additional practical experience before a pharmacist license is issued or
					 reissued; or
(e) An out-of-state
					 pharmacist enrolled in or participating in an established residency
					 program.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 2 - GENERAL LICENSING › Subpart A - Pharmacy Interns and Pharmacist › Section 246-945-156 - Pharmacy intern-Temporary practice permit

Current through Register Vol. 24-14, July 15, 2024
(1) An individual that holds a pharmacy
					 intern registration in another U.S jurisdiction, that has registration
					 standards substantially equivalent to Washington, may request a temporary
					 practice permit if:
(a) The applicant is not
					 subject to denial of a credential or issuance of a conditional or restricted
					 credential in any state;
(b) Does
					 not have a criminal record in Washington state;
(c) The applicant's fingerprint-based
					 national background check results are pending; and
(d) The applicant meets WAC
					 246-945-155 (1)(a) or
					 (b).
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 2 - GENERAL LICENSING › Subpart A - Pharmacy Interns and Pharmacist › Section 246-945-162 - Pharmacist license qualifications

Current through Register Vol. 24-14, July 15, 2024
(1) In addition to
					 the requirements in
					 RCW
					 18.64.080, an applicant for a pharmacist
					 license who holds a baccalaureate degree in pharmacy or a doctor of pharmacy
					 degree from a commission accredited school or college of pharmacy shall submit
					 documentation of education and practice experience as follows:
(a) An applicant who graduated before July 1,
					 2020, whose official transcripts confer or award a baccalaureate of pharmacy or
					 doctorate of pharmacy degree shall provide certification of at least 1500
					 pharmacy internship hours in accordance with WAC
					 246-945-163.
(b) An applicant who graduates after July 1,
					 2020, whose official transcripts confer or award a doctorate of pharmacy is
					 deemed to have satisfied the pharmacy practice experience and education
					 requirements for licensure without documentation of internship hours.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 2 - GENERAL LICENSING › Subpart A - Pharmacy Interns and Pharmacist › Section 246-945-163 - Certification of internship hours

Current through Register Vol. 24-14, July 15, 2024
Hours reported to the commission under WAC 246-945-162,
						246-945-173, and 246-945-175, shall occur as follows:
(1) Hours must be completed within eighteen
					 months from the date of graduation;
(2) From a commission accredited school or
					 college of pharmacy, U.S. jurisdiction board or commission or the supervising
					 pharmacist at the internship site;
(3) Hours shall be reported thirty days after
					 the completion of any internship experience;
(4) The documentation must include the
					 supervising pharmacist's evaluation and certification of internship hours, and
					 an intern site evaluation;
(5) If
					 the report of hours submitted to the commission indicates that the intern has
					 not adequately performed the practice of pharmacy, the commission may reject
					 all or part of the hours reported.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 2 - GENERAL LICENSING › Subpart A - Pharmacy Interns and Pharmacist › Section 246-945-165 - Pharmacist licensure and jurisprudence examinations

Current through Register Vol. 24-14, July 15, 2024
(1) Upon authorization by the commission or
					 its designee, an individual applying for a pharmacist license shall take and
					 pass a pharmacy licensure examination and jurisprudence examination approved by
					 the commission.
(2) A score of
					 seventy-five or higher is required to pass each of the examinations.
(3) An individual who fails the licensure
					 examination or jurisprudence examination three times shall not be authorized
					 for further examination until they have satisfactorily completed a study or
					 tutorial program approved by the commission.
(4) An applicant for a pharmacist license who
					 has passed an approved licensure examination in another state may transfer
					 their score to Washington to meet the commission's requirement to take and pass
					 a commission approved pharmacy licensure examination if:
(a) The applicant meets the requirements in
					 WAC 246-945-162; and
(b) The
					 applicant completes the application process to receive a pharmacist license
					 before the score transfer expires. The score transfer application will expire
					 one year from the date the department receives the score transfer
					 application.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 2 - GENERAL LICENSING › Subpart A - Pharmacy Interns and Pharmacist › Section 246-945-170 - Pharmacist licensure by license transfer-Temporary practice permits

Current through Register Vol. 24-14, July 15, 2024
(1) An individual
					 who holds an active pharmacist license, in good standing, issued by another
					 U.S. jurisdiction may apply for a pharmacist license in Washington by license
					 transfer. In addition to the completion of the commission's application, the
					 applicant must:
(a) File for license transfer
					 using the NABP eLTP process; and
(b) Take and pass the approved jurisprudence
					 examination.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 2 - GENERAL LICENSING › Subpart A - Pharmacy Interns and Pharmacist › Section 246-945-171 - Retired active pharmacist license status

Current through Register Vol. 24-14, July 15, 2024
(1) A pharmacist may apply for a retired
					 active pharmacist license status if they:
(a)
					 Hold an active pharmacist license issued by the commission under chapter 18.64
					 RCW that is in good standing;
(b)
					 Submit an application on a form provided by the commission; and
(c) Pay the retired credential status
					 application fee as specified in WAC
					 246-945-990.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 2 - GENERAL LICENSING › Subpart A - Pharmacy Interns and Pharmacist › Section 246-945-173 - Expired pharmacist license

Current through Register Vol. 24-14, July 15, 2024
To return to active status a pharmacist with an expired
						license shall pay the applicable fees in accordance with WAC 246-945-990
						through 246-945-992 and:
(1) If the pharmacist license has been
					 expired for less than three years the pharmacist shall meet the requirements of
					 WAC 246-12-040 and 15 CPE hours per
					 year the license has been expired.
(2) If the pharmacist license has been
					 expired for three years or more, and the pharmacist holds an active credential
					 in another U.S. jurisdiction, and is in good standing, the pharmacist shall:
(a) Meet the requirements of WAC
					 246-12-040;
(b) Provide certification of an active
					 pharmacist license which includes:
(i) Name
					 and license number;
(ii) Issue and
					 expiration date; and
(iii)
					 Verification that the license has not been the subject of final or pending
					 disciplinary action.
(c)
					 Submit verification of current active pharmacy practice from another U.S.
					 jurisdiction; and
(d) Take and pass
					 the commission approved jurisprudence examination.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 2 - GENERAL LICENSING › Subpart A - Pharmacy Interns and Pharmacist › Section 246-945-175 - Inactive pharmacist license

Current through Register Vol. 24-14, July 15, 2024
(1)
					 A pharmacist may obtain an inactive license by meeting the requirements of WAC
					 246-12-090 and
					 RCW
					 18.64.140.
(2) An inactive license can be renewed in
					 accordance with WAC
					 246-12-100 and by paying the
					 applicable fees in accordance with WAC
					 246-945-990 through
					 246-945-992.
(3) If a license is inactive for three years
					 or less, to return to active status a pharmacist shall meet the requirements of
					 WAC 246-12-110.
(4) If a license is inactive for more than
					 three years, and the pharmacist has been in active practice in another U.S.
					 jurisdiction, to return to active status the pharmacist must:
(a) Provide certification of an active
					 pharmacist license which includes:
(i) Name
					 and license number;
(ii) Issue and
					 expiration date; and
(iii)
					 Verification that the license has not been the subject of final or pending
					 disciplinary action.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 2 - GENERAL LICENSING › Subpart A - Pharmacy Interns and Pharmacist › Section 246-945-178 - Pharmacist continuing education

Current through Register Vol. 24-14, July 15, 2024
(1) As part of the
					 process to renew a pharmacist license, a pharmacist shall complete continuing
					 education in compliance with this section.
(2) A pharmacist shall complete the
					 equivalent of 30 hours of continuing education each license renewal cycle. The
					 30 hours of continuing education must be delivered by a continuing education
					 provider accredited by ACPE, except as provided for in subsections (4) and (5)
					 of this section.
(3) A pharmacist
					 shall register with a program designated by the commission for tracking
					 completed CPE hours.
(4) A
					 pharmacist shall complete a one-time training in suicide screening and referral
					 by the end of the first full renewal cycle after initial licensure. The
					 training must meet the following requirements:
(a) Be at least three hours long;
(b) Be from the department's model list of
					 approved suicide prevention training programs, and include content related to
					 imminent harm via lethal means; and
(c) The hours spent completing the training
					 in this subsection may count toward meeting CPE requirements.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 2 - GENERAL LICENSING › Subpart A - Pharmacy Interns and Pharmacist › Section 246-945-180 - Nuclear pharmacist endorsement

Current through Register Vol. 24-14, July 15, 2024
To receive a nuclear pharmacist endorsement, a pharmacist
						must:
(1) Be licensed to practice in
					 Washington;
(2) Meet minimal
					 standards of training and experience in the handling of radioactive materials
					 in accordance with WAC
					 246-240-075
					 and submit to the commission proof of compliance; and
(3) Receive a letter of recognition as a
					 nuclear pharmacist from the commission.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 2 - GENERAL LICENSING › Subpart B - Pharmacy Assistants and Technicians › Section 246-945-200 - Pharmacy assistants

Current through Register Vol. 24-14, July 15, 2024
(1) To become
					 registered as a pharmacy assistant an applicant shall submit an application to
					 the commission that meets the requirements of WAC
					 246-12-020.
(2) The supervising pharmacist, shall
					 instruct the pharmacy assistant regarding their scope of practice.
(3) To renew a registration a pharmacy
					 assistant shall submit an application to the commission with the applicable
					 fees in accordance with WAC
					 246-945-990 through
					 246-945-992.
Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 2 - GENERAL LICENSING › Subpart B - Pharmacy Assistants and Technicians › Section 246-945-203 - Pharmacy technician-in-training authority for experiential training

Current through Register Vol. 24-14, July 15, 2024
(1) An individual
					 who is enrolled in a commission-approved pharmacy-technician training program
					 shall obtain an endorsement for experiential training in a pharmacy for:
(a) Initial certification; or
(b) As required by the commission to complete
					 additional practice experience before a pharmacy technician certification is
					 issued, renewed, or reactivated.